medrogestone and Thromboembolism

medrogestone has been researched along with Thromboembolism* in 2 studies

Trials

1 trial(s) available for medrogestone and Thromboembolism

Article	Year
Estrogens reduce plasma histidine-rich glycoprotein (HRG) levels in a dose-dependent way. Thrombosis and haemostasis, 1995, Volume: 73, Issue:3 Plasma levels of histidine-rich glycoprotein (HRG) were investigated in three groups of women receiving a different dose of estrogens. First, the effect of low-dose estrogen was studied in a group of 83 postmenopausal women who were treated with 0.625 mg conjugated estrogens (CE). No significant change from baseline levels was found at the end of cycle 3 and cycle 13. Secondly, in 15 mothers and 23 daughters using oral contraceptives (OC) containing 30-50 micrograms ethinyl estradiol (EE) daily the mean HRG level was 14% and 24% lower than in a group of 144 mothers and 134 daughters not taking oral contraceptives, respectively (p < 0.05). Finally, in 11 excessively tall prepuberal girls who received 300 micrograms EE daily to reduce their final height the mean plasma HRG levels were decreased by 68% (p < 0.005). The effect of progestogens administered during low-dose and high-dose estrogen therapy appeared to be minor. The results from these three studies indicate that estrogens reduce plasma HRG levels in a dose-dependent way. Topics: Adolescent; Age Factors; Aged; Body Height; Child; Contraceptives, Oral, Hormonal; Dose-Response Relationship, Drug; Estrogens, Conjugated (USP); Ethinyl Estradiol; Female; Gigantism; Humans; Medrogestone; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Proteins; Risk; Thromboembolism	1995

Article

Year

Estrogens reduce plasma histidine-rich glycoprotein (HRG) levels in a dose-dependent way.

Thrombosis and haemostasis, 1995, Volume: 73, Issue:3

Plasma levels of histidine-rich glycoprotein (HRG) were investigated in three groups of women receiving a different dose of estrogens. First, the effect of low-dose estrogen was studied in a group of 83 postmenopausal women who were treated with 0.625 mg conjugated estrogens (CE). No significant change from baseline levels was found at the end of cycle 3 and cycle 13. Secondly, in 15 mothers and 23 daughters using oral contraceptives (OC) containing 30-50 micrograms ethinyl estradiol (EE) daily the mean HRG level was 14% and 24% lower than in a group of 144 mothers and 134 daughters not taking oral contraceptives, respectively (p < 0.05). Finally, in 11 excessively tall prepuberal girls who received 300 micrograms EE daily to reduce their final height the mean plasma HRG levels were decreased by 68% (p < 0.005). The effect of progestogens administered during low-dose and high-dose estrogen therapy appeared to be minor. The results from these three studies indicate that estrogens reduce plasma HRG levels in a dose-dependent way.

Topics: Adolescent; Age Factors; Aged; Body Height; Child; Contraceptives, Oral, Hormonal; Dose-Response Relationship, Drug; Estrogens, Conjugated (USP); Ethinyl Estradiol; Female; Gigantism; Humans; Medrogestone; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Proteins; Risk; Thromboembolism

1995

Other Studies

1 other study(ies) available for medrogestone and Thromboembolism

Article	Year
[Oral contraceptives: pharmacotherapy of normal women (author's transl)]. Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1976, Jan-06, Volume: 65, Issue:1 Side effects, especially cardiovascular, of oral contraception in healthy women are discussed. A causal relationship between ovulation inhibitors and thromboembolic disease has been demon demonstrated epidemiologically and experimentally. Thrombus formation may be due to disturbances of blood coagulation, lesions, of the vascular wall, or blood flow disorders; the "pill" influences all 3 components. The role of the "pill" in the etiology of hypertension has not been explained, but there is no doubt of its existence. Although the risk to a healthy woman with no predisposing factors is small, it is real, and must be considered by the patient and her physician. Topics: Cerebrovascular Disorders; Contraceptives, Oral; Contraceptives, Oral, Hormonal; Estrogens; Female; Humans; Medrogestone; Myocardial Infarction; Thromboembolism	1976

Article

Year

[Oral contraceptives: pharmacotherapy of normal women (author's transl)].

Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1976, Jan-06, Volume: 65, Issue:1

Side effects, especially cardiovascular, of oral contraception in healthy women are discussed. A causal relationship between ovulation inhibitors and thromboembolic disease has been demon demonstrated epidemiologically and experimentally. Thrombus formation may be due to disturbances of blood coagulation, lesions, of the vascular wall, or blood flow disorders; the "pill" influences all 3 components. The role of the "pill" in the etiology of hypertension has not been explained, but there is no doubt of its existence. Although the risk to a healthy woman with no predisposing factors is small, it is real, and must be considered by the patient and her physician.

Topics: Cerebrovascular Disorders; Contraceptives, Oral; Contraceptives, Oral, Hormonal; Estrogens; Female; Humans; Medrogestone; Myocardial Infarction; Thromboembolism

1976